MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.53
-0.09
-1.60%
Opening 15:11 01/27 EST
OPEN
5.39
PREV CLOSE
5.62
HIGH
5.73
LOW
5.39
VOLUME
34.07K
TURNOVER
--
52 WEEK HIGH
20.45
52 WEEK LOW
4.890
MARKET CAP
8.82M
P/E (TTM)
-0.9739
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ABIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ABIO News

  • ARCA biopharma EPS beats by $0.54
  • seekingalpha.11/07/2019 03:23
  • ARCA biopharma Q3 EPS $(0.76) Up From $(2.06) YoY
  • Benzinga.11/06/2019 21:29
  • ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
  • GlobeNewswire.11/06/2019 21:10
  • Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth?
  • Simply Wall St..11/03/2019 13:47

More

Industry

Pharmaceuticals
-0.22%
Pharmaceuticals & Medical Research
-0.33%

Hot Stocks

Name
Price
%Change

About ABIO

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
More

Webull offers Arca Biopharma Inc (ABIO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.